Major international emergencies such as the COVID-19 pandemic and the ongoing conflict in Ukraine have led to supply chain disruptions for FDA-regulated companies. During this webinar, speakers will discuss: 1) specific impacts of supply chain disruptions on FDA-regulated industry; 2) findings from the FDA’s 2021 100-day review of supply chains and reports on outcomes one year later; 3) ways that companies can mitigate risks posed by unexpected shortages or problems getting access to components of regulated products from third-party manufacturers; 4) federal efforts to stimulate domestic manufacturing of critical medical products and other FDA-regulated components; and 5) how organizations have rethought and rebuilt their supply chains to be more agile, efficient, and sustainable.
- +$100 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Christina Anderson Mooney, Senior Legal Director, Medtronic
Amy Norris, Executive Counsel, Clif Bar & Company and Member, FDLI Board of Directors
Howard R. Sklamberg, Partner, Life Sciences & Healthcare Regulatory, Arnold & Porter LLP
Moderated by Winston Kirton, Partner, BakerHostetler
Virtual Learning FAQ